Adicet Bio's ADI-001 Shows Promise in CAR T Cell Therapy for Autoimmune Diseases

Adicet Bio Advances CAR T Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc., a clinical-stage biotechnology firm, highlights significant advancements in its ADI-001 Phase 1 GLEAN trial, with clinical biomarker data set to be presented at ACR Convergence 2024 in Washington, D.C. This trial marks a pivotal moment for the company as it showcases the potential of ADI-001, an allogeneic CD20-targeted γδ CAR T cell therapy, specifically designed to address autoimmune diseases. The trial results reveal a remarkable activation of CAR T cells, with levels ranging from 27-64% of total cellular material detected through digital droplet polymerase chain reaction (ddPCR) at the 1E9 dose. These findings not only surpass those achieved by autologous alpha-beta CAR T therapies but also underscore ADI-001's robust tissue homing capabilities.

The clinical data demonstrates complete depletion of CD19+ B cells in secondary lymphoid tissues, a critical factor in combating autoimmune disorders. Dr. Francesco Galimi, Chief Medical Officer at Adicet Bio, emphasizes the importance of this therapeutic candidate, noting that ensuring complete B cell depletion in tissue is vital for addressing the unmet needs in autoimmune disease treatment. The strong activation profile of ADI-001, particularly highlighted by elevated levels of granzyme B, indicates a promising therapeutic mechanism that could enhance patient outcomes. As the company prepares for its presentation at the conference, the data reinforces the potential of ADI-001 to become a significant player in autoimmune therapies.

Adicet Bio's commitment to advancing ADI-001 is evident through its ongoing basket study targeting six autoimmune indications, supported by recent investigational new drug application (IND) clearances. Monica Moreno, Ph.D., will present the oral findings titled "ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications" on November 19, 2024. The trial's insights not only indicate a breakthrough in CAR T cell technology but also highlight the limitations of traditional anti-CD20 antibody therapies, which have struggled to effectively deplete B cells in secondary lymphoid tissues.

As Adicet Bio continues its groundbreaking work in the CAR T cell therapy space, the implications of the GLEAN trial results could reshape approaches to treating autoimmune diseases, offering hope for improved therapeutic strategies that address long-standing challenges in the field. The presentation at ACR Convergence 2024 serves as an important step in showcasing these advancements to the broader medical community.